A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Simple item page
dc.contributor.authorRinella, Mary E.
dc.contributor.authorLazarus, Jeffrey V.
dc.contributor.authorRatziu, Vlad
dc.contributor.authorFrancque, Sven M.
dc.contributor.authorSanyal, Arun J.
dc.contributor.authorKanwal, Fasiha
dc.contributor.authorRomero, Diana
dc.contributor.authorAbdelmalek, Manal F.
dc.contributor.authorAnstee, Quentin M.
dc.contributor.authorPablo Arab, Juan
dc.contributor.authorArrese, Marco
dc.contributor.authorBataller, Ramon
dc.contributor.authorBeuers, Ulrich
dc.contributor.authorBoursier, Jerome
dc.contributor.authorBugianesi, Elisabetta
dc.contributor.authorByrne, Christopher D.
dc.contributor.authorCastro Narro, Graciela E.
dc.contributor.authorChowdhury, Abhijit
dc.contributor.authorCortez-Pinto, Helena
dc.contributor.authorCryer, Donna R.
dc.contributor.authorCusi, Kenneth
dc.contributor.authorEl-Kassas, Mohamed
dc.contributor.authorKlein, Samuel
dc.contributor.authorEskridge, Wayne
dc.contributor.authorFan, Jiangao
dc.contributor.authorGawrieh, Samer
dc.contributor.authorGuy, Cynthia D.
dc.contributor.authorHarrison, Stephen A.
dc.contributor.authorKim, Seung Up
dc.contributor.authorKoot, Bart G.
dc.contributor.authorKorenjak, Marko
dc.contributor.authorKowdley, Kris V.
dc.contributor.authorLacaille, Florence
dc.contributor.authorLoomba, Rohit
dc.contributor.authorMitchell-Thain, Robert
dc.contributor.authorMorgan, Timothy R.
dc.contributor.authorPowell, Elisabeth E.
dc.contributor.authorRoden, Michael
dc.contributor.authorRomero-Gomez, Manuel
dc.contributor.authorSilva, Marcelo
dc.contributor.authorSingh, Shivaram Prasad
dc.contributor.authorSookoian, Silvia C.
dc.contributor.authorSpearman, C. Wendy
dc.contributor.authorTiniakos, Dina
dc.contributor.authorValenti, Luca
dc.contributor.authorVos, Miriam B.
dc.contributor.authorWong, Vincent Wai-Sun
dc.contributor.authorXanthakos, Stavra
dc.contributor.authorYilmaz, Yusuf
dc.contributor.authorYounossi, Zobair
dc.contributor.authorHobbs, Ansley
dc.contributor.authorVillota-Rivas, Marcela
dc.contributor.authorNewsome, Philip N.
dc.date.accessioned2025-01-20T20:10:36Z
dc.date.available2025-01-20T20:10:36Z
dc.date.issued2023
dc.description.abstractThe principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.
dc.description.funderEU-IMI2
dc.fuente.origenWOS
dc.identifier.doi10.1097/HEP.0000000000000520
dc.identifier.eissn1527-3350
dc.identifier.issn0270-9139
dc.identifier.urihttps://doi.org/10.1097/HEP.0000000000000520
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92083
dc.identifier.wosidWOS:001084349300001
dc.issue.numero6
dc.language.isoen
dc.pagina.final1986
dc.pagina.inicio1966
dc.revistaHepatology
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleA multisociety Delphi consensus statement on new fatty liver disease nomenclature
dc.typeartículo
dc.volumen78
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas